财务总监辞职，总经理暂代职责 2025 年 9 月 2 日，东北制药集团股份有限公司（以下简称 "东北制药"）发布官方公告，披露核心管理岗位人事调整：公司财务总监周雅娜女士因个人原因 申请辞去财务总监职务。根据公告安排，在公司正式聘任新财务总监前，将由董事、总经理蔡永刚先生代为行使财务总监职责，以保障财务工作的正常推 进。 根据东北制药 2025 年半年报数据，公司上半年经营业绩呈现 "营收净利润双下滑、研发投入高增长" 的特点：上半年实现营业收入 38.53 亿元，同比下滑 7.58%；归属于上市公司股东的净利润 1.29 亿元，同比下滑 17.62%，业绩承压明显。同期研发费用达 8349 万元，较去年同期大幅增长 84.09%，研发费用占 营业收入的比例约为 2.17%，反映出公司在创新领域的投入力度持续加大，试图通过研发突破缓解业绩压力。 关键岗位调整频繁，与战略及行业环境相关 此次财务总监变动并非个例，过去三年间，东北制药管理层关键岗位调整较为频繁，涉及董事、董事会秘书、副总经理、董事长等多个核心职位，具体变动 如下： 对于管理层频繁变动的原因，东北制药表示，部分调整源于公司战略优化需求及行业环境变 ...

延伸阅读： 2025年1至6月份，东北制药的营业收入构成为：医药制造业占比52.0%，医药商业占比46.18%，其他行 业占比1.82%。 长久物流:公司财务总监靳婷辞职 安孚科技:聘任刘剑波为公司财务总监 广誉远:聘任任岩为公司财务总监 每经AI快讯，东北制药（SZ 000597）9月1日晚间发布公告称，周雅娜女士因个人身体原因申请辞去公 司财务总监职务。 截至发稿，东北制药市值为82亿元。 ...

Group 1 - The financial director of Northeast Pharmaceutical Group, Ms. Zhou Yana, has resigned due to personal health reasons [1] - The resignation is effective immediately upon delivery to the board, and it will not affect the company's normal operations [1] - The board will appoint a new financial director in accordance with relevant regulations, and until then, Mr. Cai Yonggang will act in this capacity [1] Group 2 - Ms. Zhou Yana holds 120,000 shares in the company, and her shares will continue to be managed according to relevant regulations after her resignation [2] - The company expresses gratitude for Ms. Zhou Yana's diligent and faithful performance of her duties during her tenure [2]

Core Viewpoint - Northeast Pharmaceutical announced the resignation of its Chief Financial Officer, Zhou Yana, due to personal health reasons [1] Company Summary - The company's board of directors received a written resignation report from Zhou Yana [1] - Zhou Yana's resignation is attributed to personal health issues [1]

格隆汇9月1日丨东北制药(000597.SZ)公布，公司董事会于近日收到公司财务总监周雅娜女士的书面辞 职报告，周雅娜女士因个人身体原因申请辞去公司财务总监职务。 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-060 根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等法律法规及《公司章程》的有关规定，其辞职报告自送达公 司董事会之日起生效。周雅娜女士辞去公司财务总监职务不会影响公司相关工作 的正常进行。公司董事会将根据相关规定尽快聘任财务总监。在聘任财务总监之 前，由公司董事、总经理蔡永刚先生代为行使财务总监职责。 截至本公告披露日，周雅娜女士持有公司股份 120,000 股。辞去公司财务总 监职务后，其所持股份将继续按照《上市公司董事、监事和高级管理人员所持本 公司股份及其变动管理规则》《深圳证券交易所股票上市规则》《深圳证券交易 所上市公司自律监管指引第 18 号——股东及董事、监事、高级管理人员减持股 份》等相关规定进行管理。 周雅娜女士在担任公司财务总监期间，勤勉、忠实地履行了相关职责和义务， 公司及董事会对周雅娜女士表示衷心感谢！ 特此公告。 东北制药集团股份有限公司董事会 东北制药集团股份有限公司关于公司财务总监辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导 ...

Core Viewpoint - The resignation of the Chief Financial Officer (CFO) of Northeast Pharmaceutical Group Co., Ltd. due to personal health reasons will not affect the company's normal operations [1] Group 1 - The CFO, Zhou Yana, submitted a written resignation report to the board of directors [1] - The resignation is effective immediately upon delivery to the board [1] - The board will promptly appoint a new CFO, with current director and general manager Cai Yonggang acting in the interim [1] Group 2 - As of the announcement date, Zhou Yana holds 120,000 shares of the company [1] - The management of her shares will follow relevant regulations [1]

2025年8月27日，东北制药(000597.SZ)发布2025年半年度报告。截至2025年8月27日，共有5个机构投资 者披露持有东北制药A股股份，合计持股量达8.13亿股，占东北制药总股本的56.98%。其中，机构投资 者包括江西方大钢铁集团有限公司、辽宁方大集团实业有限公司、香港中央结算有限公司、招商银行股 份有限公司-南方中证1000交易型开放式指数证券投资基金、银河康乐股票A，机构投资者合计持股比 例达56.98%。相较于上一季度，机构持股比例合计上涨了1.37个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即南方中证1000ETF，持股增加占比小幅 上涨。本期较上一季度持股减少的公募基金共计1个，即银河康乐股票A，持股减少占比小幅下跌。本 期较上一季未再披露的公募基金共计1个，即银河康乐股票A。 外资态度来看，本期较上一期持股增加的外资基金共计1个，即香港中央结算有限公司，持股增加占比 达0.21%。 ...

Core Viewpoint - Northeast Pharmaceutical is actively enhancing its talent acquisition and innovation capabilities through a series of strategic initiatives, including the recruitment of high-level graduates and the establishment of a comprehensive R&D ecosystem to drive long-term growth and transformation [1][2][3]. Group 1: Talent Acquisition and Training - The company has initiated a month-long training program for over 100 newly recruited master's and doctoral graduates from prestigious universities, marking a significant step in its talent acquisition strategy [1][2]. - Northeast Pharmaceutical has conducted extensive recruitment efforts, including 35 recruitment events across 28 universities, selecting top candidates from over 1,600 applications [2]. - The company provides upgraded living accommodations for new hires, ensuring a smooth transition into their roles [2]. Group 2: Innovation and R&D Focus - The company is committed to enhancing its R&D capabilities by focusing on drug innovation, chemical drug transformation, cell therapy breakthroughs, and modernization of traditional Chinese medicine [2][6]. - Northeast Pharmaceutical has established a robust incentive mechanism to support high-quality research projects and reward significant breakthroughs, fostering a culture of innovation [2][3]. - The company aims to leverage its recent recruitment of high-level talent to strengthen its R&D team and expand its competitive edge in the biopharmaceutical sector [3][7]. Group 3: Strategic Transformation and Market Positioning - Northeast Pharmaceutical is undergoing a strategic transformation to adapt to changes in the pharmaceutical industry, with a focus on developing a complete industrial chain and enhancing its product pipeline [6]. - The company has made significant investments in acquiring technology and product lines, particularly through the acquisition of Beijing Dingcheng Peptide Source, positioning itself in the first tier of the cell therapy market [6][7]. - The company is actively developing over ten cell therapy products targeting various cancers, aiming to establish a competitive advantage in the biopharmaceutical market [6][7].

"我们持续引进高端人才，全面充实并壮大研发力量，不仅体现了公司高度重视技术创新的态度，更展 现了公司发展生物创新药的坚定决心和对未来发展的信心。"周凯表示，公司将以大规模硕博人才引进 为契机，为员工搭建成长成才平台，不断夯实并扩大在仿制药领域的领先优势，同时在生物创新药赛道 起好步，培育生物创新药业务新增长点。 值得一提的是，除具有市场竞争力的薪酬外，东北制药还为员工提供医疗费用资助福利、手机福 利、"孝敬父母金"、"方大养老金"等特色福利，将关怀从员工个人延伸至整个家庭，实现"一人入职、 全家受益"。 ● 本报记者 宋维东 来自北京大学、复旦大学、上海交通大学等知名高校的百名应届硕博毕业生汇聚东北制药，8月1日起开 启为期1个月的入职培训。目前，培训已进入尾声，新员工们也将奔赴公司各个岗位开启职业生涯。 自2018年通过混改加入辽宁方大集团以来，东北制药以更灵活的体制机制招贤纳士，用更有力度的奖励 激励技术人才，大力营造"鼓励成功、宽容失败、反对守成"的创新研发氛围，培育持续创新的体制机 制，打造综合研发创新体系，推动企业战略转型升级。"要确保企业拥有未来10年、20年乃至30年持续 发展的后劲，必须大力引 ...